The Role of Bilastine in Treating Paediatric Patients with Allergic Rhinoconjunctivitis and Urticaria

18 Feb 2021
The Role of Bilastine in Treating Paediatric Patients with Allergic Rhinoconjunctivitis and Urticaria
Bilastine is a second-generation antihistamine that has proven efficacy in treating urticaria and both seasonal and perennial allergic rhinitis.1,2 It has been shown to have a rapid onset of action with fast effect as early as 30 minutes, and prolonged duration of effect of more than 24 hours in adults.2–4 In paediatric patients, the therapeutic dose was identified based on the results of a pharmacokinetic study demonstrating that bilastine 10 mg once daily in children aged 2 to 11 years offers the same systemic exposure as 20 mg once daily in adults.

Resources

The Role of Bilastine in Treating Paediatric Patients with Allergic Rhinoconjunctivitis and Urticaria

The Role of Bilastine in Treating Paediatric Patients with Allergic Rhinoconjunctivitis and Urticaria

The Role of Bilastine in Treating Paediatric Patients with Allergic Rhinoconjunctivitis and Urticaria

The Role of Bilastine in Treating Paediatric Patients with Allergic Rhinoconjunctivitis and Urticaria